Source: Health Sciences Authority (SG) Revision Year: 2022 Publisher: Kowa Company, Ltd., 6-29, Nishiki 3-chome, Naka-ku, Nagoya, Aichi, JAPAN
PARMODIA film-coated tablets 0.1 mg.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. White round film-coated tablets debossed ‘Kowa 217’ on one face and a score line on the reverse. The tablet can be divided into equal halves. |
Each film-coated tablet contains 0.1 mg of pemafibrate.
For a full list of excipients see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Pemafibrate |
Pemafibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist and activates PPARα by binding to this receptor and regulates the target gene expression, leading to decreased plasma triglyceride (TG) concentration, decreased triglyceride-rich lipoprotein, decreased apolipoprotein (Apo) C-3, and increased HDL-cholesterol. |
| List of Excipients |
|---|
|
Tablet core: Lactose hydrate Film coating: Hypromellose |
PVC/Aluminium blisters in an aluminium-laminated bag, in a carton of 100 tablets (10 blisters x 10 tablets).
Kowa Company, Ltd., 6-29, Nishiki 3-chome, Naka-ku, Nagoya, Aichi, JAPAN
SIN16492P
18 May 2022
| Drug | Countries | |
|---|---|---|
| PARMODIA | Japan, Singapore |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
